Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV

Journal of Virology

Volumn 75, Issue 13, 2001, Pages 5772-5777

  Balzarini, J ^a   Camarasa, M J ^a   Perez Perez M J ^a   San Felix A ^a   Velazquez S ^a   Perno, C F ^a   De Clercq, E ^a   Anderson, J N ^a   Karlsson, A ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTIMETABOLITE; ANTIRETROVIRUS AGENT; GUANINE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRUS GENE; VIRUS GENOME;

ANTI-HIV AGENTS; ANTIMETABOLITES; DEOXYCYTOSINE NUCLEOTIDES; DRUG RESISTANCE, MICROBIAL; GENOME, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; THYMIDINE; THYMINE NUCLEOTIDES;

EID: 0034990846     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.13.5772-5777.2001     Document Type: Article

References (40)

1. 1,2,3-Triazole-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β- D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″- oxathiole-2″,2″-dioxide) (TSAO) analogues. Synthesis and anti-HIV-1 activity
2. A conserved drug target in the HIV genome
3. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2′-oxathiole-2″,2″-dioxide) pyrimidine (TSAO) nucleoside analogues: Novel highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase
4. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase
5. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)]- β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors
6. The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins
7. A highly defective HIV group O provirus: Evidence for the role of local sequence determinants in hypermutation during negative strand DNA synthesis
8. Nucleotide composition as a driving force in the evolution of retroviruses
9. High rates of frameshift mutations within homo-oligomeric runs during a single cycle of retroviral replication
10. 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: Synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo- and -ribofuranose]-3′-spiro-5″-[4″-amino-1″,2″- oxathiole 2″,2″-dioxide] (TSAO) pyrimidine nucleosides
11. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
12. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
13. Compositional similarities between the human immunodeficiency virus and surface antigens of pathogens
14. A new type of G→A hypermutation affecting human immunodeficiency virus
15. Hydroxyurea and didanosine as a more potent combination than hydroxyurea and zidovudine
16. Human infection by genetically diverse SIVsm-related HIV-2 in West Africa
17. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides
18. Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation
19. HIV-1 isolates are rapidly evolving quasispecies: Evidence for viral mixtures and preferred nucleotide substitutions
20. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G→A hypermutation
21. Selective depletion of DNA precursors. An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus
22. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins
23. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
24. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication
25. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
26. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations
27. Reverse transcriptase and substrate dependence of the RNA hypermutagenesis reaction
28. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools
29. Macrophage infection by HIV-1: Viral reservoirs and pathogenesis
30. Tenth anniversary perspectives on AIDS, HIV: Between past and future
31. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138
32. Synthesis of 1[1-[2′,5′-bis-T-(t-butyldimethylsilyl)-(β-D-xylo- and β-D-ribofuranosyl)thymine]-3′-spiro-5″-[4″-amino-1 ″,2″-oxathiole-2″,2″-dioxide]] (TSAO). A novel type of specific anti-HIV agents
33. Mechanisms of retroviral mutation
34. Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes
35. G→A hypermutation of the human immunodeficiency virus type 1 genome: Evidence for dCTP pool imbalance during reverse transcription
36. HIV genetic variation is directed and restricted by DNA precursor availability
37. Manganese cations increase the mutation rate of human immunodeficiency virus type 1 ex vivo
38. Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkyl carbamoyl 1,2,3-triazole-TSAO analogues
39. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase
40. Erratic G→A hypermutation within a complete caprine arthritis-encephalitis virus (CAEV) provirus